Pacific Edge today welcomes the release of new
research supporting the clinical utility of the company’s
genomic biomarker test Cxbladder Monitor in the surveillance
for bladder cancer recurrence.
The independent study2
is to be published in the prestigious journal Urologic
Oncology and was undertaken at the University of California
San Francisco (UCSF) and the University of Michigan. It
examined whether a negative Cxbladder Monitor test could
safely postpone a patient’s next scheduled cystoscopy, the
current ‘gold standard’ for bladder cancer
surveillance.
The study covered a sample of 92
US-based patients under surveillance for bladder cancer
recurrence during the COVID pandemic lockdown. The patients
– under the virtual supervision of their clinicians – opted
to use Cxbladder Monitor leveraging Pacific Edge’s Patient
In-Home Sampling System (PIHSS) as a first step to overcome
pandemic-related limits on clinical evaluation slots and the
risks of COVID infection during travel to and from
appointments.
Of the sample, 66 patients tested
negative for Cxbladder Monitor. Of those, 52 patients
underwent a follow up cystoscopy, and all were tumor free
– a result that supports the growing portfolio of evidence
that Cxbladder Monitor can safely reduce surveillance
cystoscopies without compromising cancer detection3.
Meanwhile, a patient satisfaction survey of those who took
the Cxbladder Monitor test at UCSF revealed strong patient
acceptance for the test and the PIHSS.4
The authors,
while suggesting the value of further validation, said:
“Cxbladder Monitor may be safely utilized to reduce the
intensity of surveillance cystoscopy and appears acceptable
to patients as an in-home test.”
Pacific Edge
Diagnostics USA Vice President of Medical Affairs Dr Tamer
Aboushwareb said: “These results represent an exciting
incremental addition to the evidence supporting the clinical
utility of Cxbladder Monitor in safely reducing the
frequency of surveillance cystoscopy across all Non-Muscle
Invasive Bladder Cancer patients and improving patient
compliance.
“The sample size and the difficulties
the researchers faced in following up all those patients
that tested Cxbladder Monitor negative represent obvious
limitations to the current study. But the absence of tumors
in all patients that had a follow up cystoscopy and the
strong patient endorsement of the test and our patient in
home sampling system are great examples of the value of our
tests.”
“We are also encouraged that the study
considered patients with medical histories that broadly
spanned the spectrum of recurrence risk, as defined by the
American Urological Association and included both primary
and recurrent tumors,” Dr Aboushwareb said.
“These
results therefore further support the clinical utility of
Cxbladder Monitor in diverse populations. We are looking
forward to building on this study with our own clinical
research program and the broad range of independent studies
focused on Cxbladder taking place around the
world.”
Further detail of Pacific Edge’s ongoing
clinical study program can be found on the company’s website.
1
PEB has not released the information contained in
this release to the NZX or ASX as it does not regard it to
be material, as defined in the NZX Listing Rules and Section
231 of the FMC Act.
2 The study, “Cxbladder
Monitor testing to reduce cystoscopy frequency in patients
with bladder cancer”, was completed with no involvement or
financial support from PEDUSA. Weblink
3
Six of the 66 CxbM negative patients did not return for a
follow up cystoscopy, four elected to undergo a further CxbM
test rather than a cystoscopy and the remaining four
patients either stopped surveillance or died of unrelated
causes. Nine of the 24 patients that tested Cxbladder
Monitor positive and then had an immediate clinical
evaluation and cystoscopy were found to have cancer
including one patient that had cancer in the upper
tract.
4 41 of the 57 patients at UCSF
completed the survey and rated the PiHSS on ease of use on a
scale of 1 to 5 (5 easiest) and whether they would consider
using CxbM to skip cystoscopies in the future. The survey
delivered a median response of ‘5’ for the first
question, while 73% responded ‘yes’ to the
second.
© Scoop Media



















Discussion about this post